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Synergistic effectAbstract Dextromethorphan is the most commonly used over-the-counter anti-tussive and expec-
torant medicine at therapeutic doses. Due to easy availability, euphoric high and hallucinogenic
effects at larger doses, dextromethorphan popularity amongst the drug abusers is growing day
by day. It is often mixed with alcohol, opiates, cannabinoids or other drugs of abuse for recreational
purposes despite their lethal synergistic effects. More than 50 deaths were reported the ﬁrst time in
Pakistan after consuming cough syrups containing dextromethorphan, manufactured by two local
pharmaceutical industries. All deceased had the history of drug abuse. We report the deaths of nine-
teen males, ages ranged from 17 to 45 years, in two major cities of Pakistan who purposefully
ingested large doses of dextromethorphan for recreational purposes and died as a result of direct
toxic effects of the drug. Toxicological analysis revealed high levels of dextromethorphan ranging
from 7.3 to 41.7 mg/L in the peripheral blood, 4.2–92.6 mg/kg in the liver and 9.9–349.6 mg/L in
the gastric content by high performance liquid chromatography. The dextromethorphan concentra-
tions in all subjects signiﬁcantly exceeded the therapeutic range and were consistent with concentra-
tions reported in other cases of dextromethorphan abuse and toxicity. Besides dextromethorphan
other drugs of abuse like cannabinoids, opiates, benzodiazepines, ethanol and chlorpheniramine
were also detected. The cause of death was determined to be acute dextromethorphan intoxication
with lethal synergistic effect of other co-ingested drugs of abuse. The deaths resulted in the prose-
cution of all individuals involved in manufacturing, distribution or sale of the cough syrup.
ª 2015 The International Association of Law and Forensic Sciences (IALFS). Production and hosting by
Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Dextromethorphan (DXM) is amongst the most abused over-
the-counter (OTC) anti-tussive medications due to its easy
availability for consumption. Buying a bottle of cough syrup
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Its popularity amongst drug abusers is growing day by day
owing to highly dose dependent effects of DXM.1,2 It acts as
cough suppressant at therapeutic doses but at larger doses it
produces intoxication, euphoric high, hallucinations, out of
body experiences, and dream-like visions.3,4 DXM is a non-
controlled drug which is structurally related to codeine (opiate)
but lacks opiate-like analgesic activity. It is manufactured as a
white powder, but consumption is by swallowing gel capsules,
tablets, or cough syrup. In cough and cold preparations, DXM
is present in combination with analgesic, decongestant, anti-
histamine, and/or expectorant/mucolytic agents.1–4
Therapeutic level of DXM reported in the literature ranges
from 0.005 to 0.06 mg/L in blood whereas the lethal levels
range from 3.3 to 9.5 mg/L in the blood and 31–230 mg/kg
in the liver.1,2
Drug abusers also mix DXM with alcohol, cannabinoids,
opiates and benzodiazepines to create an even stronger but
dangerous effect. Its effects are similar to dissociative hallu-
cinogens like phencyclidine (PCP) and lysergic acid diethy-
lamide (LSD) but not long lasting as compared to PCP and
LSD.8 DXM causes psychological addiction. FDA issued a
warning in May 2005 about the dangers of DXM abuse involv-
ing over-the-counter products and DXM obtained from illicit
sources.5 In 2005 and 2006, nearly 1 million (1.7%) and about
3.1 million persons aged 12–25 (5.3%) had misused an over-
the-counter (OTC) cough and cold medication to get high.6,7
Several deaths had been reported in the literature as a result
of direct toxic effects of DXM owing to its growing popularity
amongst young teens and young adults for recreational
purposes.2,11,13
More than 50 deaths were reported in two incidents in
Pakistan after ingesting cough syrup containing DXM in
2013. In this article, we report the deaths of nineteen subjects
who purposefully ingested cough syrup containing DXM for
recreational purposes in combination with other drugs of
abuse including benzodiazepines, opiates, cannabinoids, chlor-
pheniramine and ethanol. They died as a result of direct toxic
effects of DXM as well as lethal synergistic effect of co-
ingested drugs of abuse.
2. Case histories
2.1. Incident 1 – Lahore, Pakistan
An incident of more than 30 deaths occurred in Lahore city of
Pakistan due to ingestion of cough syrup containing DXM.
Autopsy specimens of twelve males with ages ranging from
18 to 45 years were submitted for forensic postmortem toxicol-
ogy. All subjects had the history of ingesting cough syrup man-
ufactured by a local pharmaceutical industry. Interviews with
families and friends of deceased reported that they were drug
abusers. The autopsy reports submitted with postmortem spec-
imens revealed an opiate-type overdose resulting in pulmonary
and cerebral oedema, congested lungs and other airways and
no signs of trauma or antecedent natural disease. No frag-
ments of tablets or capsules were present in the gastric contents
of all deceased. Postmortem toxicology was performed on
specimens of whole blood and gastric contents belonged to
twelve deceased. Toxicology revealed a peripheral blood
DXM concentration ranged from 7.3 to 41.7 mg/L by liquidchromatography. Chlorpheniramine (sedating anti-histamine)
was also detected but not quantitated. All subjects tested pos-
itive for the presence of opiates, eight for cannabinoids, and
two for benzodiazepines by immunoassay. Gastric contents
of one deceased also contained 1.1 g/dL ethanol. The cause
of death in all deceased was determined to be acute DXM
intoxication, and the manner of death was ruled accidental
in nature. Presence of one or more co-ingested drugs of abuse
suggested the lethal synergistic effect.
Three additional teenage males, who survived after toxic
dose of DXM, informed the police that they became ill soon
after ingesting the cough syrup and subsequently vomited.
The surviving individuals told the police that they had pur-
chased the DXM cough syrup bottles from local pharmacies
on multiple occasions. They further told police that they had
abused the same amount of medication in the past without
ill side effects.
2.2. Incident 2 – Gujranwala, Pakistan
A second incident of more than 20 DXM-related deaths
occurred in Gujranwala city of Pakistan and was linked to
the abuse of an over-the-counter cough syrup containing
DXM manufactured by another National pharmaceutical
industry. Postmortem specimens of seven deceased, ages rang-
ing from 17 to 45 years, submitted for toxicological analysis
included liver and gastric contents. Blood specimens were
not submitted for analysis. Autopsy reports submitted with
specimens showed the same opiate-type overdose with signiﬁ-
cant pulmonary oedema as in the incident 1. Postmortem tox-
icology revealed high levels of DXM ranging from 4.2 to
92.6 mg/kg in the liver and 9.9–349.6 mg/L in gastric contents.
All subjects also tested positive for the presence of opiates,
three for cannabinoids and two were positive for the presence
of benzodiazepines by immunoassay. In ﬁve deceased, 0.02–
0.43 g/dL ethanol was also found in the gastric contents. The
cause of death in all subjects was determined to be the drug
intoxication by ingestion of DXM in the presence of other
drugs of abuse, and the manner of death was accidental.
Both incidents and all deaths were linked to the cough
syrup containing DXM, manufactured by two local pharma-
ceutical industries. The owners of both industries told the
investigators that they bought the DXM (active ingredient in
cough syrup) in bulk from India, manufactured the syrup,
and sold it as over-the-counter medication. Both pharmaceuti-
cal industries were sealed and all the individuals involved were
arrested.
3. Discussion
Dextromethorphan (DXM) is the principal active ingredient of
cough and cold medications, in combination with anti-
histamine (like chlorpheniramine, pheniramine, brompheni-
ramine), analgesic (such as aspirin, acetaminophen), expecto-
rant (or mucolytic agent like guaifenesin) and/or
decongestant (like pseudoephedrine, phenylephrine). DXM is
a dextrorotatory isomer of 3-methoxy-N-methyl-methorphan
and structurally related to codeine but lacks analgesic activity.
It is a NMDA receptor antagonist. Like ketamine and phency-
clidine, the dissociative and hallucinogenic effects of DXM are
due to its binding to the NMDA receptor.9 It is metabolized in
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methoxymorphinan.10 Reported signs and symptoms associ-
ated with mild to moderate DXM intoxication includes eupho-
ria, stupor, hyperexcitability, laughing, nystagmus, mydriasis,
nausea, vomiting and diaphoresis. Dissociative psychotic dis-
orders including hallucinations, delusions, rhabdomyolysis,
hyperthermia, seizures, coma and death occur with intensive
abuse1–4,11–13. DXM also has competitive 5HT1 agonist activ-
ity and inhibits the serotonin reuptake therefore creating the
potential for interaction with selective serotonin reuptake inhi-
bitors (SSRI) like ﬂuoxetine14 and paroxetine,15 the co-
ingested anti-histamines like chlorpheniramine and, to a lesser
extent, diphenhydramine.16 Co-administration or overdosing
or co-ingestion of drugs with serotonergic effects results in a
life threatening serotonin syndrome.17 Therefore, co-ingested
drugs have potential signiﬁcance in evaluating a DXM death.
Total daily dose of DXM to relief cough is 90–120 mg
which is given four times a day in divided doses. Its single dose
(30 mg) given four times daily for a week achieved peak
plasma concentrations averaged 2.4 lg/L (range 0.5–
5.9 lg/L) in rapid metabolizers and 207 lg/L (182–231 lg/L)
in poor metabolizers18 DXM has very low cross-reactivity on
opiate or phencyclidine immunoassays and in therapeutic
doses it is generally not detected in routine toxicological anal-
ysis. Recommended analytical cut-off concentration of DXM
to perform drug-impaired driving analysis is 20 lg/L.19 A
speciﬁc immunoassay is also available for DXM.20
Several DXM-related deaths had been reported in impaired
drivers in Wisconsin21 where whole blood DXM concentra-
tions averaged 51 lg/L (range 5–1800 lg/L). In another inci-
dent, ﬁve drivers in Washington State died after consuming
1500 mg DXM.22 All of them had documented abuse histories
of recreational DXM abuse and their blood DXM concentra-
tion averaged 790 lg/L (range 470–1220 lg/L).
In most of the cases related to DXM toxicity, cough and ﬂu
preparations were abused where DXM was compounded with
other drugs, most notably the sedating antihistamine, chlor-
pheniramine. An adult suicidal poisoning case was reported
by Kintz and Mangin23 in which concentrations of DXM and
antihistamine terfenadine determined were 5090 lg/L and
7200 lg/L respectively. The terfenadine concentration was
highly elevated and undoubtedly contributed to this death.
Two DXM-related deaths were reported by Rammer et al.24
The ﬁrst death was a suicidal ingestion by an 18 year old woman
and the blood DXM concentration found was 9200 lg/L. The
second case had blood DXM concentration of 3300 lg/L.
Nine deaths were reported by Yoo et al.25 related to combined
abuse of DXMand zipeprol with amedianDXM concentration
of 1800 lg/L (ranged 1100–18,000 lg/L). Pediatric literature
also reported the deaths in infants due to administration of inap-
propriately large doses of cough and ﬂu preparations containing
DXM. Cause of death declared in these cases was DXM over-
dose as well as multiple drug intoxication.26,27
The reported acute dose of DXM for dissociative hallucino-
genic effects by the drug abusers is 150–1500 mg or more3,4
which is well above the recommended therapeutic anti-
tussive dose (90–120 mg). Five deaths were reported in three
incidents in Florida, Washington and Virginia states of
America due to abuse of DXM sold over the internet.28 In
these deaths, blood DXM concentrations averaged 1890 lg/L
(ranged 950–3230 lg/L).The incidents of dextromethorphan-related deaths reported
in this article were of healthy males in their late teens. Each
had some history of abusing large amounts of DXM cough
syrup speciﬁcally for its hallucinogenic effects. They were all
ignorant of the toxicity related to DXM overdose as well as
the lethal synergistic effects of co-ingested drugs of abuse that
they were using in addition to DXM. Lethal levels of DXM
reported in the literature ranged from 3.3 to 9.5 mg/L in the
blood and 31–230 mg/kg in the liver whereas the concentra-
tions of DXM determined in these nineteen deaths ranged
7.3–41.7 mg/L in blood, 4.2–92.6 mg/kg in the liver and 9.9–
349.6 mg/L in gastric contents. In addition to DXM, the pres-
ence of other drugs of abuse especially chlorpheniramine, ben-
zodiazepines, opiates, cannabinoids and ethanol suggested the
multiple drug intoxication. The concentrations of DXM
obtained in these cases are highly elevated and undoubtedly
contributed to these deaths. The most probable mechanism
of deaths is the generalized CNS and respiratory depressions
due to DXM overdose and lethal synergistic effect of co-
ingested drugs. All manufacturers and distributors of DXM
cough syrups were arrested and are being prosecuted. The case
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